Allogene Therapeutics's total assets for Q3 2025 were $439.77M, a decrease of -6.55% from the previous quarter. ALLO total liabilities were $124.44M for the fiscal quarter, a -1.26% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.